Editorial

The FDA's Rejection of MDMA-Assisted Psychotherapy for PTSD: A Short-Sighted Decision with Far-Reaching Consequences

Tyler Kjorvestad, MD

The U.S. Food and Drug Administration's (FDA) recent decision to reject MDMA-assisted therapy (MDMA-AT) for the treatment of post-traumatic stress disorder (PTSD) has ignited a robust debate within both medical and psychological communities. This decision, rendered despite promising clinical trial results, underscores a pivotal moment in the evolving landscape of psychedelic medicine. In June 2024, the FDA's advisory committee expressed concerns over the study design, the potential for abuse, and the absence of long-term safety data, leading to a vote not to recommend MDMA-AT, which ultimately came to fruition at the August 2024 meeting [1]. The rejection comes at a time when mental health issues, particularly PTSD, are increasingly recognized as major public concerns, with conventional treatments often falling short, especially for severe cases.

In the general population, the lifetime prevalence of PTSD is estimated to be around 7-8%, with women being twice as likely as men to develop the disorder (Kessler et al., 2005). Annually, the incidence rate of PTSD can vary, but it is generally noted that approximately 3.5% of adults in the United States develop PTSD each year [2]. The annual economic impact of PTSD in the United States is estimated to be over $42 billion, including direct medical expenses and indirect costs such as lost wages and decreased productivity [3].

Furthermore, individuals with PTSD have a significantly increased risk of suicide. The lifetime suicide risk for individuals with PTSD is significantly higher than for the general population, with PTSD patients being up to six times more likely to attempt suicide [4]. Both the economic impact and elevated suicide risk necessitate the need for effective interventions and support systems to adequately and effectively treat PTSD.

The treatment options for PTSD are limited and often inadequate for severe cases. Conventional treatments such as Selective Serotonin Reuptake Inhibitors (SSRIs), cognitive behavioral therapy (CBT), and prolonged exposure therapy are typically most helpful in mild to moderate PTSD and have diminishing returns in more severe and refractory PTSD patients [5].

Additionally, the infrastructure supporting mental health treatment is under siege. Physician and nursing shortages, coupled with the underfunding of mental health services, only compound the issues of ineffective medication and psychotherapy options.
MDMA, when used in a controlled therapeutic setting, has shown remarkable results in reducing symptoms of PTSD. MDMA facilitates the therapeutic process by reducing fear and defensiveness, allowing patients to revisit and process traumatic memories more effectively [6]. The drug's ability to enhance empathy and trust between the patient and the therapist provides a unique therapeutic benefit unachievable in traditional psychotherapy alone.

In a phase 3 trial, 86.5% of MDMA-AT participants demonstrated clinically meaningful improvement. Moreover, 71.2% of MDMA-AT participants no longer met DSM-5 criteria for PTSD by the study's end. The treatment led to more significant reductions in CAPS-5 scores and improved functional impairment as measured by the Sheehan Disability Scale [7].

In contrast, SSRIs such as sertraline and paroxetine are commonly prescribed for

PTSD, with studies suggesting that about 20-30% of patients achieve complete remission with these antidepressants alone [8,9]. While SSRIs can help reduce symptoms, they are often more effective when combined with psychotherapy. Trauma-focused therapies like Cognitive Behavioral Therapy (CBT) and Eye Movement Desensitization and Reprocessing (EMDR) have shown higher remission rates compared to antidepressants alone, ranging from 30% to 50%, with some studies reporting even higher rates depending on the duration and intensity of the therapy [10,11]. Combining antidepressants with psychotherapy often yields better outcomes than either treatment alone, with remission rates around 40-60% [12]. This combination approach, which is even more effectively demonstrated in MDMA-AT, highlights how leveraging the strengths of both pharmacological and psychological interventions provides a more comprehensive treatment strategy for patients suffering from PTSD.

CONCLUSION

MDM-AT produces improvements beyond the standard of care for patients suffering from PTSD. MDMA-AT leverages MDMA's capacity to enhance empathy, trust, and emotional openness, facilitating a therapeutic process that traditional talk therapies might not [6]. The FDA's decision to not approve MDMA-AT affects patients' immediate access to a transformational treatment option and also sends a chilling message regarding the regulatory hurdles for psychedelic therapies. The rejection of MDMA-assisted therapy leaves a significant gap in treatment options, potentially condemning many to prolonged suffering or reliance on less effective or more side-effect-laden treatments. The medical community, policymakers, and patient advocates must continue to push for a reevaluation of MDMA-AT.

AUTHOR INFORMATION

Tyler Kjorvestad, M.D.
(tkjorvestad@kumc.edu)

Kjorvestad, T, (2024, September). The FDA's Rejection of MDMA-Assisted Psychotherapy for PTSD: A Short-Sighted Decision with Far-Reaching Consequences. *The Journal of Psychedelic Psychiatry*, *6*(3).

REFERENCES:

1. Reardon, S. (2024). MDMA therapy for PTSD rejected by FDA panel. *Nature*. https://doi.org/10.1038/d41586-024-01622-3
2. *Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 617-627.*
3. Kilpatrick, D. G., Resnick, H. S., Milanak, M. E., Miller, M. W., Keyes, K. M., & Friedman, M. J. (2013). National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. Journal of Traumatic Stress, 26(5), 537-547.
4. Gradus, J. L. (2017). PTSD and death from suicide. National Center for PTSD. Retrieved from https://www.ptsd.va.gov/professional/treat/cooccurring/suicide_ptsd.asp
5. APA. (2017). *Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD)
6. Mithoefer, M. C., et al. (2019). *MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 trials*. Psychopharmacology, 236(9), 2785-2801. https://doi.org/10.1037/pas0000486

7. MAPS. (2021). *Phase 3 Trials of MDMA-Assisted Psychotherapy for PTSD*
8. Stein, M. B., Ipser, J. C., & Seedat, S. (2006). Pharmacotherapy for post-traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews, (1), CD002795. doi:10.1002/14651858.CD002795.pub2 Hoskins, M., Pearce, J., Bethell, A., Dankova, L.,
27
9. Barbui, C., Tol, W. A., ... & Bisson, J. I. (2015). Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. The British Journal of Psychiatry, 206(2), 93-100. doi:10.1192/bjp.bp.114.148551Wohlfarth,
10. Bradley, R., Greene, J., Russ, E., Dutra, L., & Westen, D. (2005). A multidimensional meta-analysis of psychotherapy for PTSD. American Journal of Psychiatry, 162(2), 214-227. doi:10.1176/appi.ajp.162.2.214
11. Bisson, J. I., Roberts, N. P., Andrew, M., Cooper, R., & Lewis, C. (2013). Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. Cochrane Database of Systematic Reviews, (12), CD003388. doi:10.1002/14651858.CD003388.
12. Foa, E. B., Keane, T. M., Friedman, M. J., & Cohen, J. A. (Eds.). (2009). Effective treatments for PTSD: Practice guidelines from the International Society for Traumatic Stress Studies. Guilford Press. van der Kolk, B. A., Dreyfuss, D., Michaels, M., Shera, D., Berkowitz, R., Fisler, R., & Saxe, G. (1994). Fluoxetine in posttraumatic stress disorder. The Journal of Clinical Psychiatry, 55(12), 517-522.